-
公开(公告)号：KR1020170043887A
公开(公告)日：2017-04-24
申请号：KR1020150143524
申请日：2015-10-14
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/02 , A61K8/31 , A61K8/73 , A61K8/84 , A61K8/92 , A61L27/14 , A61Q19/08
Abstract: 본발명은중앙에형성된공동및 상기공동을둘러싸는미세기공을포함하는격벽을포함하는중공형다공성미립구를포함하는피부조직재생또는피부조직볼륨증진주사용조성물에관한것이다. 본발명에따른조성물에포함되는중공형다공성미립구는작은입자크기를가짐으로써주사를통해피부조직내로투여될수 있으며, 상기공동내에서상기이동한피부조직세포가효과적으로증식할수 있다. 일정기간경과후 상기중공형다공성미립구가피부내에서생분해된후에도상기새롭게증식된피부조직세포가그 부피를유지하므로, 피부조직재생효과를안전하고오랫동안유지할수 있다.
Abstract translation: 本发明涉及一种皮肤组织再生或皮肤组织体积增强组合物，其包含具有中心形成的空腔和包含围绕该空腔的微孔的隔膜的导血多孔微粒。 包含在本发明组合物中的中空芯多孔微粒具有小的粒径并且可以通过注射注射到皮肤组织中，并且迁移的皮肤组织细胞可以有效地在腔中传播。 因为后的一定时间内已经在皮肤内的可生物降解的共形多孔微球之后经过，新增殖组织细胞维持其体积可以保持安全和长期皮肤组织再生的效果。
-
公开(公告)号：KR1020160118146A
公开(公告)日：2016-10-11
申请号：KR1020160038558
申请日：2016-03-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/46 , A61K8/73 , A61K8/735 , A61L27/20 , A61L27/54 , A61L27/58 , A61L2300/412 , A61Q19/00 , A61Q19/08
Abstract: 본발명은피부재생촉진용조성물에관한것으로서, 보다상세하게는소듐 2-메르캅토에탄설포네이트를함유함으로써우수한피부재생효과를갖는조성물에관한것이다.
-
13.发明授权바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 有权其新颖的化合物异构体或其药学上可接受的盐作为包含它们的泛脲受体拮抗剂和药物组合物
公开(公告)号：KR101645537B1
公开(公告)日：2016-08-05
申请号：KR1020090108632
申请日：2009-11-11
Applicant: (주)아모레퍼시픽
IPC: C07D323/04 , A61K31/357
Abstract: 본발명은바닐로이드수용체(Vanilloid Receptor 1; VR1; TRPV1) 길항제로작용하는신규화합물, 이의이성질체또는이의약제학적으로허용가능한염; 및이를포함하는약학조성물에관한것이다. 본발명은통증, 편두통(migraine), 관절통(arthralgia), 신경통(neuralgia), 신경장해(neuropathies), 신경손상(nerve injury), 피부질환(skin disorder), 비뇨방광과민증(urinary bladder hypersensitiveness), 과민성대장증후군(irritable bowel syndrome), 절박배변(fecal urgency), 호흡기질환(respiratory disorder), 위-십이지장궤양(stomach-duodenal ulcer), 염증질병(inflammatory diseases), 귓병(ear disease), 심장병(heart disease) 등과같은질병의예방또는치료용약학조성물을제공한다.
-
公开(公告)号：KR1020120059429A
公开(公告)日：2012-06-08
申请号：KR1020110126601
申请日：2011-11-30
Applicant: (주)아모레퍼시픽
IPC: A61K31/16 , A61K8/40 , A61Q19/00 , C07K14/435
Abstract: PURPOSE: A composition containing panthenol, polyalcohol ester compounds, casein, or derivative thereof is provided to stably maintain the peptides or proteins. CONSTITUTION: A peptide or protein stabilizing agent contains panthenol, polyalcohol ester compounds, and casein or derivative thereof. The peptide or protein contains growth factors, hormone, interferon, vaccine, recombinant protein, recombinant peptide, or enzyme. The polyalcohol ester compound or derivative is polyglyceryl distearate, PEG distearate, polyglyceryl methyl glucose distearate, or PEG methyl glucose distearate. A cosmetic composition contains the peptide or protein stabilizing agent.
Abstract translation: 目的：提供含有泛醇，多元醇酯化合物，酪蛋白或其衍生物的组合物以稳定地维持肽或蛋白质。 构成：肽或蛋白质稳定剂含有泛醇，多元醇酯化合物，酪蛋白或其衍生物。 肽或蛋白质含有生长因子，激素，干扰素，疫苗，重组蛋白，重组肽或酶。 多元醇酯化合物或衍生物是二硬脂酸聚甘油酯，二硬脂酸PEG，聚甘油甲基葡萄糖二硬脂酸酯，或PEG甲基葡萄糖二硬脂酸酯。 化妆品组合物含有肽或蛋白质稳定剂。
-
公开(公告)号：KR1020120027436A
公开(公告)日：2012-03-21
申请号：KR1020117031696
申请日：2010-06-18
Applicant: (주)아모레퍼시픽
CPC classification number: A61Q19/005 , A61K8/97 , A61K36/49
Abstract: PURPOSE: A cosmetic composition containing nutshell extract is provided to suppress proteinase-activated receptor-2(PAR-2) and to relieve itching. CONSTITUTION: A cosmetic composition for relieving or suppressing itching contains nutshell extract as an active ingredient. The composition prevents or relieves itching caused by inflammatory dermatitis, atopic dermatitis, miliaria, frostbite, contact dermatitis, seborrheic dermatitis, or pruritus. A cosmetic composition improving skin barrier function contains the nutshell extract as an active ingredient. The extract is prepared using water, low alcohol of C1-4, 1,3-butylene glycol, or mixture thereof.
Abstract translation: 目的：提供含有坚果壳提取物的化妆品组合物，以抑制蛋白酶激活的受体-2（PAR-2）并缓解瘙痒。 构成：用于缓解或抑制瘙痒的化妆品组合物含有坚果壳提取物作为活性成分。 该组合物预防或缓解由炎症性皮炎，特应性皮炎，睫毛膏，冻伤，接触性皮炎，脂溢性皮炎或瘙痒引起的瘙痒。 改善皮肤屏障功能的化妆品组合物含有坚果壳提取物作为活性成分。 提取物是使用C 1-4，1,3-丁二醇或其混合物的水，低级醇制备的。
-
Patent Agency Ranking16.发明公开바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 有权新型化合物，异构体或其药学上可接受的盐作为VANULLOID受体拮抗剂和含有其的药物组合物
公开(公告)号：KR1020100053470A
公开(公告)日：2010-05-20
申请号：KR1020090108632
申请日：2009-11-11
Applicant: (주)아모레퍼시픽
IPC: C07D323/04 , A61K31/357
Abstract: PURPOSE: A novel compound which functions as a vanilloid receptor 1(VR1) antagonist is provided to prevent or treat disease related to hair growth, rhinitis, and pancreatitis. CONSTITUTION: A vanilloid receptor antagonist compound is denoted by chemical formula I. A pharmaceutical composition contains the compound, isomer, or pharmaceutically acceptable salt thereof. The composition is used for preventing or treating arthritis disease, neuropathy, HIV related neuropathy, nerve injury, neurodegeneration, cerebral apoplexy, urinary incontinence, cough, neuropathy/allergy/inflammation skin disease, atopic dermatitis, psoriasis, pruritus, the prurigo, acouesthesia, aliasing, bregma anaphylaxis, effluvium, or alopecia.
Abstract translation: 目的：提供作为香草素受体1（VR1）拮抗剂起作用的新型化合物，以预防或治疗与毛发生长，鼻炎和胰腺炎有关的疾病。 构成：香草素受体拮抗剂化合物由化学式I表示。药物组合物含有化合物，异构体或其药学上可接受的盐。 该组合物用于预防或治疗关节炎疾病，神经病，HIV相关神经病，神经损伤，神经变性，脑中风，尿失禁，咳嗽，神经病变/过敏/炎症皮肤病，特应性皮炎，牛皮癣，瘙痒，瘙痒症，麻醉， 混叠，原发性过敏性反应，流出或脱发。
-
公开(公告)号：KR1020080050786A
公开(公告)日：2008-06-10
申请号：KR1020060121508
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/133
Abstract: A method for inducing itch and a method for screening an itch inhibiting material using glucosylsphingosine are provided to be useful for studying and understanding the itch, thereby being very usefully used for developing a therapeutic agent for the itch and evaluating the effect of a medicine. A method for inducing itch comprises a step of administering at least one compound selected from the group consisting of glucosylsphingosine and a derivative thereof into an animal except human. A method for screening an itch inhibiting material comprises the steps of: (a) administering an itch inhibition candidate material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A method for evaluating the itch inhibition effect comprises the steps of: (a) administering an itch inhibition material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A composition for inducing itch comprises at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof as an effective ingredient.
Abstract translation: 提供诱导瘙痒的方法和使用葡糖基鞘氨醇来筛选瘙痒抑制物质的方法，可用于研究和理解瘙痒，从而非常有用地用于开发瘙痒治疗剂并评估药物的效果。 诱导瘙痒的方法包括向除人之外的动物中施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物的步骤。 筛选瘙痒抑制物质的方法包括以下步骤：（a）通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物，向瘙痒诱导的动物施用瘙痒抑制候选物质; 和（b）当动物划伤时计数。 评估瘙痒抑制效果的方法包括以下步骤：（a）向通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物诱导瘙痒的动物施用瘙痒抑制物质; 和（b）当动物划伤时计数。 用于诱导瘙痒的组合物包含至少一种选自葡糖基鞘氨醇及其衍生物的化合物作为有效成分。
-
公开(公告)号：KR1020080034575A
公开(公告)日：2008-04-22
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: A method for inhibiting the expression of CCL27/CTACK(Cutaneous T-cell-attracting chemokine) is provided to regulate SPC(sphingosylphosphorylcholine) inducing expression of CCL27/CTACK, so that the method is useful for prevention and treatment of diseases associated with overexpression of CCL27/CTACK including atopic dermatitis, psoriasis and inflammatory skin disease. The expression of CCL27/CTACK is inhibited by administering an effective amount of sphingosylphosphorylcholine regulator capable of inhibiting activity of SPC or competing with the mechanism of SPC inducing overexpression of CCL27/CTACK to a mammal requiring the expression reduction of CCL27/CTACK. A method for screening the SPC regulator comprises the steps of: (1) treating a testing cell such as keratinocyte with 2-10 muM of SPC or its derivatives to induce overexpression of CCL27/CTACK; and (2) treating the overexpression of CCL27/CTACK-induced cell with a candidate material and measuring the expression inhibition of CCL27/CTACK. Further, the mammal has an atopic dermatitis or psoriasis.
Abstract translation: 提供抑制CCL27 / CTACK（皮肤T细胞吸引趋化因子）表达的方法，以调节诱导CCL27 / CTACK表达的SPC（鞘氨醇磷酰胆碱），从而该方法可用于预防和治疗与过表达相关的疾病 CCL27 / CTACK包括特应性皮炎，牛皮癣和炎性皮肤病。 通过施用有效量的能够抑制SPC活性或与诱导CCL27 / CTACK过表达的SPC的机制竞争需要CCL27 / CTACK表达降低的哺乳动物，CCL27 / CTACK的表达被抑制。 用于筛选SPC调节剂的方法包括以下步骤：（1）用2-10μM的SPC或其衍生物处理测试细胞如角质细胞，以诱导CCL27 / CTACK的过度表达; 和（2）用候选物质治疗CCL27 / CTACK诱导的细胞的过度表达，并测量CCL27 / CTACK的表达抑制。 此外，哺乳动物具有特应性皮炎或牛皮癣。
-
公开(公告)号：KR1020070107961A
公开(公告)日：2007-11-08
申请号：KR1020060040588
申请日：2006-05-04
Applicant: (주)아모레퍼시픽
IPC: A61K36/9068 , A61K36/754
CPC classification number: A61K36/00 , A61K8/97 , A61K9/00 , A61K36/754 , A61K36/9062 , A61K36/9068 , A61K2236/33 , A61Q19/00 , A61Q19/005 , Y10S514/857
Abstract: A composition comprising extracts of crude drugs is provided to suppress and relieve itching caused by inflammatory and atopic dermatitis without side effects such as toxicity and skin irritation. A composition for suppressing and relieving itching comprises 0.1-10 wt.% of the extracts of Zingiber officinale Rosc., Evodia officinalis and Alpinia katsumadai Hayata which are prepared by extracting them with water, C1-C4 lower alcohol or a mixed solvent thereof. The daily dosage of crude drug extracts is 0.001-100 mg/kg, preferably 0.1-30 mg/kg and the composition is a pharmaceutical composition having a formulation selected from ointment, plaster, lotion and liniment, or a cosmetic composition having a formulation selected from skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
Abstract translation: 提供包含生药提取物的组合物以抑制和缓解由炎性和特应性皮炎引起的瘙痒，而没有副作用，例如毒性和皮肤刺激。 用于抑制和缓解瘙痒的组合物包括通过用水，C1-C4低级醇或其混合溶剂提取它们制备的姜黄提取物的0.1-10重量％的提取物。 生药提取物的日剂量为0.001-100mg / kg，优选0.1-30mg / kg，并且组合物是具有选自软膏，石膏，洗剂和搽剂的制剂的药物组合物或具有选择的制剂的化妆品组合物 从皮肤洗剂，皮肤柔肤剂，皮肤调色剂，收敛剂，乳液，乳液，滋润乳液，营养乳液，按摩霜，营养霜，保湿霜，护手霜，粉底，精华，营养精华，包装，肥皂，清洁泡沫，清洁 洗剂，清洁霜，身体乳液和身体清洁剂。
-
-
-
-
-
-
-
-
-
Search Results
68
records
(took 0.041 seconds)
